Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, Manika K, Kioumis IP, van der Werf TS, Johnson JL, Peloquin C, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00384-19. doi: 10.1128/AAC.00384-19. Print 2019 Jul.

PMID:
31010868
2.

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.

Clin Pharmacokinet. 2019 Apr 17. doi: 10.1007/s40262-019-00763-3. [Epub ahead of print]

PMID:
30997650
3.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
4.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
5.

Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.

Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S303-S307. doi: 10.1093/cid/ciy613.

PMID:
30496466
6.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

PMID:
30496460
7.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

8.

An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.

Mieras LF, Taal AT, van Brakel WH, Cambau E, Saunderson PR, Smith WCS, Prakoeswa CRS, Astari L, Scollard DM, do Nascimento DC, Grosset J, Kar HK, Izumi S, Gillini L, Virmond MCL, Sturkenboom MGG.

BMC Infect Dis. 2018 Oct 5;18(1):506. doi: 10.1186/s12879-018-3402-4.

9.

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313. doi: 10.1093/jac/dky152.

10.

Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring.

Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S44-S45. doi: 10.1016/j.ijmyco.2016.07.003. Epub 2016 Aug 8.

11.

Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.

Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. No abstract available.

PMID:
27931348
12.

Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.

Sturkenboom MG, Akkerman OW, van Altena R, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1237-1239. doi: 10.1183/13993003.00986-2016. Epub 2016 Aug 4. No abstract available.

13.

Therapeutic Drug Monitoring of Posaconazole: an Update.

Dekkers BGJ, Bakker M, van der Elst KCM, Sturkenboom MGG, Veringa A, Span LFR, Alffenaar JC.

Curr Fungal Infect Rep. 2016;10:51-61. doi: 10.1007/s12281-016-0255-4. Epub 2016 May 7. Review.

14.

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.

Ghimire S, Bolhuis MS, Sturkenboom MG, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Jun;47(6):1867-9. doi: 10.1183/13993003.00040-2016. Epub 2016 Mar 17. No abstract available.

15.

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

Hofman S, Segers MM, Ghimire S, Bolhuis MS, Sturkenboom MG, Van Soolingen D, Alffenaar JW.

Expert Opin Emerg Drugs. 2016;21(1):103-16. doi: 10.1517/14728214.2016.1151000. Epub 2016 Feb 20. Review.

PMID:
26848966
16.

End TB with precision treatment!

van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015. No abstract available.

17.

Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.

Saktiawati AM, Sturkenboom MG, Stienstra Y, Subronto YW, Sumardi, Kosterink JG, van der Werf TS, Alffenaar JW.

J Antimicrob Chemother. 2016 Mar;71(3):703-10. doi: 10.1093/jac/dkv394. Epub 2015 Dec 11.

PMID:
26661397
18.

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.

19.

An interlaboratory quality control programme for the measurement of tuberculosis drugs.

Aarnoutse RE, Sturkenboom MG, Robijns K, Harteveld AR, Greijdanus B, Uges DR, Touw DJ, Alffenaar JW.

Eur Respir J. 2015 Jul;46(1):268-71. doi: 10.1183/09031936.00177014. Epub 2015 Apr 16. No abstract available.

20.

Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future.

Sturkenboom MG, Akkerman OW, Bolhuis MS, de Lange WC, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Apr;59(4):2474. doi: 10.1128/AAC.05173-14. No abstract available.

21.

Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method.

Dijkstra JA, Sturkenboom MG, Hateren Kv, Koster RA, Greijdanus B, Alffenaar JW.

Bioanalysis. 2014 Aug;6(16):2125-33. doi: 10.4155/bio.14.191.

PMID:
25331857
22.

Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply.

Buurman DJ, Vande Casteele N, Sturkenboom MG, Kleibeuker JH, Vermeire S, van der Kleij D, Rispens T, Gils A, Dijkstra G.

Aliment Pharmacol Ther. 2013 Jan;37(2):282. doi: 10.1111/apt.12128. No abstract available.

23.

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G.

Aliment Pharmacol Ther. 2012 Oct;36(8):765-71. doi: 10.1111/apt.12030. Epub 2012 Aug 28.

24.

Rifampicin treatment of persistently elevated benzodiazepine metabolites in a comatose patient.

Panday PV, Vischjager P, Rodgers MG, Maurer JM, Sturkenboom MG, Nijsten MW.

Intensive Care Med. 2009 Sep;35(9):1647-8. doi: 10.1007/s00134-009-1529-x. Epub 2009 Jun 17. No abstract available.

25.

A randomised controlled trial assessing the effect of oral diazepam on 18F-FDG uptake in the neck and upper chest region.

Sturkenboom MG, Hoekstra OS, Postema EJ, Zijlstra JM, Berkhof J, Franssen EJ.

Mol Imaging Biol. 2009 Sep-Oct;11(5):364-8. doi: 10.1007/s11307-009-0207-2. Epub 2009 Mar 27.

26.

The diagnostic value of 124I-PET in patients with differentiated thyroid cancer.

Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, Wolffenbuttel BH, Dierckx RA, Links TP.

Eur J Nucl Med Mol Imaging. 2008 May;35(5):958-65. doi: 10.1007/s00259-007-0660-6. Epub 2008 Jan 4.

27.

Fatal intracranial haemorrhage associated with the administration of low-molecular-weight-heparin in a child.

van Heerde M, Sturkenboom MG, Zweegman S, Labadie J, Plötz FB.

Eur J Pediatr. 2005 Sep;164(9):589-90. Epub 2005 Jun 3. No abstract available.

PMID:
15933857
28.

Physiological uptake of [18F]fluorodeoxyglucose in the neck and upper chest region: are there predictive characteristics?

Sturkenboom MG, Franssen EJ, Berkhof J, Hoekstra OS.

Nucl Med Commun. 2004 Nov;25(11):1109-11.

PMID:
15577589

Supplemental Content

Loading ...
Support Center